Peter Lawson
Stock Analyst at Barclays
(1.47)
# 3,507
Out of 5,044 analysts
100
Total ratings
41.86%
Success rate
-10.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $315.43 | +22.06% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $32.37 | +23.57% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $22.17 | +12.77% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $9.33 | -67.85% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $39.99 | +0.03% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.91 | +57.07% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.55 | +29.03% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.05 | +737.89% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $6.42 | +55.76% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.31 | +73.16% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $14.27 | -57.95% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $11.04 | -0.36% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $9.65 | +65.80% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $8.12 | +84.73% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $18.60 | -24.73% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.42 | +111.27% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $2.28 | +31.58% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.28 | +212.50% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $57.99 | +3.47% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $7.38 | +130.35% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $13.11 | +151.72% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $33.46 | +97.25% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $11.98 | +158.76% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $7.77 | +67.31% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.71 | +192.40% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $3.36 | +4.17% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $100.35 | +263.73% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $43.08 | +6.78% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $62.57 | +619.19% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $3.25 | +1,284.62% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $65.72 | -31.53% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $315.43
Upside: +22.06%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $32.37
Upside: +23.57%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $22.17
Upside: +12.77%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $9.33
Upside: -67.85%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $39.99
Upside: +0.03%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.91
Upside: +57.07%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.55
Upside: +29.03%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.05
Upside: +737.89%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $6.42
Upside: +55.76%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.31
Upside: +73.16%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $14.27
Upside: -57.95%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $11.04
Upside: -0.36%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $9.65
Upside: +65.80%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $8.12
Upside: +84.73%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $18.60
Upside: -24.73%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.42
Upside: +111.27%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $2.28
Upside: +31.58%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.28
Upside: +212.50%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $57.99
Upside: +3.47%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $7.38
Upside: +130.35%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $13.11
Upside: +151.72%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $33.46
Upside: +97.25%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $11.98
Upside: +158.76%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $7.77
Upside: +67.31%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.71
Upside: +192.40%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $3.36
Upside: +4.17%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $100.35
Upside: +263.73%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $43.08
Upside: +6.78%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $62.57
Upside: +619.19%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $3.25
Upside: +1,284.62%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $65.72
Upside: -31.53%